| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 1/200-1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000 | Human,Mouse,Rat |
| Aliases | SGK1; SGK; Serine/threonine-protein kinase Sgk1; Serum/glucocorticoid-regulated kinase 1 |
| Entrez GeneID | 6446; |
| WB Predicted band size | 54kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from human SGK1 around the non-phosphorylation site of S78. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是关于SGK1抗体的3篇参考文献示例(文献信息及摘要内容为模拟，非真实文献)：
---
1. **文献名称**：*SGK1 regulates renal sodium transport and blood pressure*
**作者**：Lang F, Pearce D
**摘要**：研究利用SGK1特异性抗体分析其在肾脏组织中的表达，发现SGK1通过调控钠离子通道(ENaC)活性影响血压稳态，抗体验证了SGK1蛋白在高血压模型中的上调。
---
2. **文献名称**：*Role of SGK1 in diabetic nephropathy: Insights from antibody-based detection*
**作者**：Chen Y, et al.
**摘要**：通过Western blot和免疫组化(使用SGK1抗体)证实，糖尿病肾病中SGK1表达升高与肾小管纤维化相关，抑制SGK1可缓解病理损伤。
---
3. **文献名称**：*SGK1 promotes cancer cell survival under hypoxia*
**作者**：Zhang L, et al.
**摘要**：研究利用SGK1抗体检测肿瘤细胞中蛋白定位，发现缺氧条件下SGK1激活mTOR通路并抑制凋亡，提示其作为癌症治疗潜在靶点。
---
4. **文献名称**：*Antibody validation for SGK1 phosphorylation studies in neuronal cells*
**作者**：Kumar A, et al.
**摘要**：通过质谱和免疫沉淀(使用SGK1特异性抗体)验证了神经元中SGK1的磷酸化位点，揭示其在氧化应激反应中的信号调控机制。
---
(注：以上为模拟内容，实际文献需通过PubMed/Google Scholar等平台检索关键词“SGK1 antibody”或“serum/glucocorticoid-regulated kinase 1”获取。)
Serum and glucocorticoid-regulated kinase 1 (SGK1) is a ubiquitously expressed serine/threonine kinase belonging to the AGC kinase family. It plays a critical role in cellular stress responses, ion transport regulation, and cell survival by integrating signals from hormones (e.g., glucocorticoids), growth factors, and metabolic cues. SGK1 is activated via the PI3K/AKT/mTOR pathway and phosphorylates downstream targets like Nedd4-2. ENaC, and NKCC to modulate sodium homeostasis, potassium excretion, and cellular proliferation. Dysregulation of SGK1 has been linked to pathologies including hypertension, cancer progression, diabetes, fibrosis, and neurodegenerative disorders.
SGK1 antibodies are essential tools for studying its expression, localization, and activation status (e.g., phosphorylated forms) in tissues or cell lines. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to explore SGK1's role in disease mechanisms or therapeutic interventions. Commercial SGK1 antibodies are typically raised against specific epitopes (e.g., human SGK1 N-terminal or catalytic domains) and validated for cross-reactivity in human, mouse, or rat samples. Some antibodies distinguish between SGK1 isoforms (SGK1. SGK2. SGK3) or detect post-translational modifications. Recent research highlights SGK1's dual roles in cancer—promoting tumor survival under stress while potentially inhibiting metastasis—and its involvement in metabolic disorders, making SGK1 antibodies pivotal for both basic research and preclinical studies targeting kinase activity.
×
